NeonMind Biosciences has filed a new patent application with the U.S. Patent and Trademark Office related to a novel mechanism of weight loss targeted to specific fat subtypes.
The provisional patent application includes data derived from NeonMind’s recent preclinical animal study, incorporating novel findings which indicate, in addition to reiterating weight modulation effects of psilocybin seen in previous studies, that the targeted reduction of specific fat subtypes may have beneficial effects on metabolic and cardiovascular health.
Category Press Release
Published in Benzinga
Companies Featured
NeonMindNeonMind are exploring using psilocybin as an innovative approach to weight loss.